EquiReason

EquiReason research coverage

ZoomInfo Technologies Inc. GTM

Technology · Software - Application

24quarters analysed
12SEC filings read
3segments identified
10institutional managers tracked

Segments it reports

The business segments ZoomInfo Technologies Inc. reports in its own SEC filings.

  • Reportable Segment

Product lines it reports

The product and service lines ZoomInfo Technologies Inc. breaks its revenue into.

  • Subscription And Circulation
  • Email Verification Service And Contact Data
  • Other Service

Where its revenue is reported

The geographies ZoomInfo Technologies Inc. reports revenue for. How much comes from each is in the product.

  • United States

What we read

The sources behind this company, and how many records of each we hold.

  • Financial statements26
  • Quarterly metric series12
  • Business segments3
  • SEC filings12
  • Deals and transactions1
  • Insider transactions (Form 4)6
  • Institutional positions (13F)7
  • Earnings events1
  • Earnings quality checks5
  • Estimate revisions11
  • GAAP vs non-GAAP reconciliation1
  • Seasonal pattern6
  • Multi-period trajectory7
  • Inflection detection1
  • Fiscal calendar1
  • Index membership4

What we look for

Every company is run through the same checks. Both answers are reported — a signal we looked for and did not find is as much a fact as one we did.

  • Revenue series24
  • Margin series1
  • Cash flow series24
  • Earnings series24
  • Per-share series1
  • Operating cash flow series24
  • Guidance changesnot found

This page says how much of ZoomInfo Technologies Inc. we have read. What any of it means — the direction, the dates, the evidence and what would overturn it — is inside the product.

Open GTM in EquiReason

This page publishes coverage counts and reported breakdown names, but no financial figures, price data, rankings or investment conclusions. Sources are SEC filings, earnings calls and public institutional disclosures. How the research is made · All companies

ZoomInfo Technologies Inc. (GTM) — research coverage | EquiReason